. Key inclusion and exclusion criteria Key inclusion criteria 1) Patients with HbA1c (NGSP value) between 7.0% and 10.5% at the time informed consent was obtained. 2) Patients who had been receiving a specific diet for more than 8 weeks, at the time of the initiation of luseogliflozin treatment. 3) Patients who had not taken any anti-diabetes agents for more than 8 weeks or had been taking one oral hypoglycemic agent at the same dose. 4) Patients with a BMI between 20.0 and 35.0 at the time informed consent was obtained. 5) Patients (regardless of sex) who were aged 20 to 65 years at the time informed consent was obtained. 6) Outpatients. 7) Patients who received an explanation before the participation in the study and who understood the contents and provided written informed consents by themselves. Key exclusion criteria 1) Patients with diabetes mellitus, other than type 2 diabetes mellitus (type 1 diabetes mellitus, diabetes mellitus due to specific mechanism/ diseases other than type 2 and gestational diabetes, etc.). 2) Patients with severe renal impairment (nephrotic syndrome, renal failure and dialysis procedure, etc.). 3) Patients with severe hepatic dysfunction (hepatic cirrhosis, etc.). 4) Patients with severe cardiac disorder (cardiac failure, etc.), myocardial infarction and cerebral infarction or a previous history of these diseases within 6 months prior to the study. 5) Patients with severe diabetic microangiopathy (despite continuous treatment, or due to inadequately-controlled diabetic retinopathy or diabetic neuropathy, etc.). 6) Patients with a malignant tumor or a previous history of malignant tumors (however, those who were not treated for them, or did not have a recurrence at the time of the study were included). 7) Patients who had a history of hypersensitivity to luseogliflozin. 8) Severe chronic drinkers. 9) Pregnant or possibly pregnant women, women who hoped to be pregnant, and women who were lactating during the study. 10) Those considered inappropriate for the study by the physicians in charge of the study.
